Cefotetan

DRUG NAME: Cefotetan

---

⚠️ AVAILABILITY WARNING — CRITICAL FOR INDIAN PRESCRIBERS

• International clinical guidelines (particularly US-origin surgical prophylaxis and PID treatment guidelines that recommend cefotetan by name)
• Clinical trials and international literature
• Imported drug supplies for specific patients or institutions
• Comparative pharmacology discussions with cefoxitin (the Indian alternative)

---

Chemical Classification Note

1. Confers resistance to hydrolysis by many beta-lactamases (including some chromosomal AmpC beta-lactamases that inactivate true cephalosporins)
2. Provides clinically significant anaerobic activity — particularly against Bacteroides fragilis group — which true second-generation cephalosporins (cefuroxime, cefaclor, cefprozil) lack

• Cefotetan — NOT available in India (this monograph)
• Cefoxitin — AVAILABLE in India (the practical alternative)

1. ⚠️ Disulfiram-like reaction with alcohol
2. ⚠️ Hypoprothrombinemia / coagulopathy (vitamin K antagonism)

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• IV (slow IV injection / bolus over 3–5 minutes, or intermittent IV infusion over 20–60 minutes)
• IM (deep intramuscular injection)

---

Biosimilar Status:

---

Formulations Available in India

⛔ NOT CURRENTLY MARKETED IN INDIA

---

Formulations Available Globally (For Reference)

---

FDCs and Banned Formulations

• No FDCs containing cefotetan exist
• No cefotetan-containing formulation has been banned in India (as the drug has never been marketed here)

---

PHARMACOKINETICS

Primary PK Table

---

NMTT Side Chain — Clinically Critical Pharmacological Feature

---

• Post-operative patients (bleeding risk at surgical site)
• Malnourished patients (common in Indian hospital populations)
• Patients on concurrent anticoagulants

---

PK-PD Target (Antimicrobial-Specific)

---

Post-Antibiotic Effect (PAE)

---

Spectrum of Activity

---

Comparative Pharmacokinetic & Pharmacological Table: Cefotetan vs Cefoxitin vs Cefuroxime

---

Key Clinical PK Distinctions of Cefotetan

---

Population Pharmacokinetic Notes

---

Cefotetan vs Amoxicillin-Clavulanate — Comparator for Mixed Aerobic-Anaerobic Infections

1. Cefoxitin (direct cephamycin substitute — same pharmacological class, available in India)
2. Amoxicillin-clavulanate (broader coverage including enterococci, available IV + oral, NLEM-listed)
3. Cephalosporin + metronidazole (e.g., cefuroxime IV/oral + metronidazole IV/oral — both NLEM-listed, provides aerobic + anaerobic coverage, IV-to-oral step-down possible)
4. Ampicillin-sulbactam (available in India — good anaerobic coverage, no NMTT risk)
5. Piperacillin-tazobactam (for more severe/healthcare-associated infections)

---

ADULT INDICATIONS + DOSING

---

⚠️ CRITICAL AVAILABILITY REMINDER

---

⚠️ ANTIMICROBIAL STEWARDSHIP NOTES FOR CEFOTETAN

• Surgical prophylaxis (colorectal, gynaecological)
• Mixed aerobic-anaerobic infections (intra-abdominal, pelvic)

• Cefoxitin (available in India — preferred cephamycin alternative)
• Amoxicillin-clavulanate IV (available in India — NLEM-listed)
• Ampicillin-sulbactam IV (available in India)
• Cephalosporin + metronidazole combination (widely available in India)

• For clean surgical prophylaxis (orthopaedic, cardiac, hernia) where anaerobic coverage is NOT needed: Use cefazolin (NLEM-listed, cheaper, better MSSA activity, no NMTT risk)
• For pure gram-positive SSTIs: Use cefazolin or cloxacillin (NLEM-listed)
• For community-acquired respiratory infections: Use cefuroxime or amoxicillin-clavulanate (NLEM-listed, oral step-down available)
• For uncomplicated UTI: Use nitrofurantoin or fosfomycin (NLEM-listed, oral)

• ⚠️ ESBL prevalence in Indian E. coli: 40–70% (hospital), 20–40% (community) — cefotetan/cefoxitin are NOT reliably active against ESBL producers
• ⚠️ B. fragilis group resistance to cephamycins: 15–30% (variable by centre; increasing trend)
• ⚠️ AmpC-producing Enterobacterales (Enterobacter, Citrobacter, Serratia): cephamycins may select for resistant mutants on therapy
• ICMR AMR surveillance data (most recent) should be consulted for local resistance patterns before choosing empirical therapy for any infection where cefotetan or its alternatives are considered

• ⛔ MRSA infections
• ⛔ ESBL-producing gram-negative infections
• ⛔ Pseudomonas infections
• ⛔ Enterococcal infections
• ⛔ Meningitis (poor CSF penetration)
• ⛔ Gonorrhoea (use ceftriaxone per NACO/ICMR/WHO guidelines)
• ⛔ Atypical pneumonia as monotherapy

---

GENERAL ADULT DOSING REFERENCE TABLE

• Starting dose: Full therapeutic dose from first administration (no loading dose; no titration for antibiotics)
• Titration: Not applicable
• Usual maintenance dose: 1–2 g IV q12h (indication-dependent)
• Maximum dose: Max 3 g per dose (exceptional); Max 6 g per day (exceptional — rarely used in practice; standard maximum is 4 g/day for most indications)

---

Primary Indications (Approved / Standard)

---

Indication 1: SURGICAL PROPHYLAXIS — Colorectal, Gynaecological, and Clean-Contaminated Procedures

1. When to prefer cefotetan over alternatives:
   • (a) Clinical scenario where cefotetan has an advantage: When a single pre-operative dose providing combined aerobic + anaerobic coverage is desired for procedures lasting up to 6 hours WITHOUT intraoperative re-dosing. Cefoxitin’s short half-life (~45–60 min) requires re-dosing every 2–3 hours intraoperatively — logistically challenging in long procedures.
   • (b) This makes cefotetan a convenient first-choice for prolonged colorectal/GYN surgeries — but NOT superior in terms of spectrum or outcomes.
   • © Compared against: cefoxitin (shorter t½, needs re-dosing), cefazolin + metronidazole (two-drug combination), amoxicillin-clavulanate IV (comparable coverage, but different spectrum nuances).
   • ℹ️ For India: Since cefotetan is unavailable, the practical choice is cefoxitin or cefazolin + metronidazole. If the procedure is expected to be prolonged (>3 hours), the two-drug combination (cefazolin + metronidazole) may be simpler than re-dosing cefoxitin.
2. When NOT to use cefotetan for surgical prophylaxis:
   • ⛔ Clean surgery (no anaerobic flora exposure) — use cefazolin alone
   • ⛔ Suspected/confirmed MRSA colonisation — add vancomycin
   • ⛔ Patient on warfarin/acenocoumarol — NMTT side chain → additive coagulopathy risk; use cefoxitin or cefazolin + metronidazole instead
   • ⛔ Patient with history of disulfiram-like reactions or who may consume alcohol post-operatively within 72 hours
   • ⛔ Continuation beyond 24 hours post-operatively — no benefit, increased risk
3. NLEM India: ❌ Cefotetan is NOT listed in NLEM India 2022. For surgical prophylaxis, NLEM-listed options include: cefazolin injection (1 g), cefuroxime injection (750 mg, 1.5 g), metronidazole injection (500 mg/100 mL).
4. Time to expected clinical response: Not applicable — prophylaxis, not treatment. Efficacy measured by absence of surgical site infection (SSI) at 30-day post-operative assessment.
5. Criteria for treatment failure: Development of SSI despite prophylaxis → obtain wound culture, initiate therapeutic antibiotics based on susceptibility. Do NOT extend prophylactic antibiotics beyond 24 hours as ”extended prophylaxis“ — this does not prevent SSI and promotes resistance.
6. Mandatory baseline investigations: Allergy history (cephalosporin/penicillin). If using cefotetan specifically: baseline PT/INR (NMTT coagulopathy risk). Not required for cefoxitin or cefazolin alternatives.
7. Specialist initiation: Not required — any surgeon/anaesthesiologist can prescribe surgical prophylaxis.
8. Indian guideline source: AIIMS Surgical Prophylaxis Protocol; NCDC Infection Control Guidelines; ASHP/IDSA/SIS Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery (2013) — Bratzler DW, et al. (international, adapted for Indian practice). API Textbook — Surgical Site Infections chapter.
9. Key disease-specific safety warning:
   ⚠️ NMTT-specific for cefotetan: If cefotetan prophylaxis is used (e.g., from imported supply), ensure the patient has NO access to alcohol-containing products (beverages, medications, tonics) for 72 hours after administration. Also check baseline PT/INR — a single prophylactic dose rarely causes clinically significant coagulopathy, but patients with pre-existing coagulopathy or liver disease are at risk.
10. Common dose adjustment scenarios: Renal impairment — see Renal Adjustment (Part 3); standard single prophylactic dose generally does NOT require renal adjustment. Obesity (BMI ≥30): use the 2 g dose.

---

Indication 2: PELVIC INFLAMMATORY DISEASE (PID) — Inpatient Treatment (CDC Regimen)

1. When to prefer cefotetan over alternatives for PID:
   • (a) Cefotetan’s advantage in PID: q12h dosing vs cefoxitin’s q6h, providing the same spectrum coverage with fewer daily IV infusions. Combined aerobic + anaerobic coverage in a single agent without needing to add metronidazole separately.
   • (b) This makes cefotetan a convenient alternative to cefoxitin for inpatient PID — but NOT superior in efficacy. Clinical outcomes are equivalent.
   • © Compared against: cefoxitin (q6h — more nursing workload), ceftriaxone + doxycycline ± metronidazole (outpatient alternative — no anaerobic coverage from ceftriaxone alone).
   • ℹ️ For India: Use cefoxitin 2 g IV q6h + doxycycline 100 mg oral q12h as the direct substitution. If cefoxitin is unavailable at a specific institution: ampicillin-sulbactam 3 g IV q6h + doxycycline or amoxicillin-clavulanate 1.2 g IV q8h + doxycycline provide reasonable alternatives.
2. When NOT to use:
   • ⛔ Outpatient PID (mild-moderate) — does not need IV therapy; use outpatient CDC Regimen (ceftriaxone IM single dose + doxycycline oral ± metronidazole oral)
   • ⛔ Suspected gonococcal PID with known cefotetan resistance (rare, but gonococcal susceptibility to second-generation cephamycins is declining)
   • ⛔ Patient on anticoagulants — NMTT coagulopathy risk; use cefoxitin or ampicillin-sulbactam instead
   • ⛔ If TOA requires drainage — surgical/interventional drainage is the primary treatment; cefotetan/cefoxitin is adjunctive
3. NLEM India: ❌ Not listed. For PID, NLEM-listed components include: ceftriaxone injection, doxycycline, metronidazole.
4. Time to expected clinical response: Clinical improvement (defervescence, reduced pelvic tenderness, declining WBC/CRP) expected within 48–72 hours. If no improvement by 72 hours → reassess: imaging (TOA? other pathology?), surgical consultation, broaden antibiotics.
5. Treatment failure criteria: Persistent fever and pelvic pain at 72 hours, enlarging TOA on imaging, development of peritonitis, new organ dysfunction. Consider: CT/MRI pelvis, interventional drainage of TOA, switch to broader-spectrum regimen (e.g., carbapenem + clindamycin/metronidazole), and gynaecological surgical consultation.
6. Mandatory baseline investigations:MANDATORY: Pregnancy test (rule out ectopic pregnancy), STI screening (GC/CT NAAT — nucleic acid amplification test), pelvic ultrasound (to evaluate for TOA), CBC, CRP/ESR, HIV and syphilis screening (NACO guidelines for all PID patients). RECOMMENDED: Blood cultures if systemically unwell, endocervical swab for Gram stain/culture.
7. Specialist initiation: Inpatient PID management typically by O&G specialist or infectious disease physician. Not primary care.
8. Indian guideline source: CDC STI Treatment Guidelines 2021 (international reference — widely used in Indian O&G practice); FOGSI Guidelines on PID; API Textbook — Gynaecological Infections; ICMR NACO STI Treatment Guidelines.
9. Key disease-specific safety warning:
   ⚠️ Always rule out ectopic pregnancy before diagnosing PID — ectopic pregnancy is a life-threatening surgical emergency that can mimic PID symptoms. Pregnancy test is MANDATORY before starting any PID regimen.
   ⚠️ Partner notification and treatment — all sexual partners from the preceding 60 days must be tested and empirically treated for gonorrhoea and chlamydia.
10. Common dose adjustment scenarios: Renal impairment — adjust cefotetan per CrCl (Part 3). No hepatic adjustment for cefotetan itself, but monitor PT/INR if liver disease (NMTT risk amplification).
11. ℹ️ Investigation misconception flag: ℹ️ CA-125 is NOT useful for diagnosing PID — CA-125 can be elevated in PID but is non-specific (also elevated in endometriosis, ovarian malignancy, peritonitis, pregnancy). Do NOT order CA-125 as a PID diagnostic test. Diagnosis is primarily clinical (CDC clinical criteria) supplemented by imaging and microbiological testing.

---

Indication 3 (Combined): INTRA-ABDOMINAL INFECTIONS + URINARY TRACT INFECTIONS + SKIN AND SOFT TISSUE INFECTIONS + LOWER RESPIRATORY TRACT INFECTIONS + BONE AND JOINT INFECTIONS

• (a) Identical dosing range: 1–2 g IV (or IM for less severe)
• (b) Identical routes: IV (preferred) or IM
• © Identical frequency: Every 12 hours (q12h)
• (d) Differ ONLY in: duration of therapy, severity-based dose selection, and disease-specific clinical notes

---

---

1. When to prefer cefotetan: Single-agent coverage of both aerobic gram-negatives and anaerobes (B. fragilis) for community-acquired IAI without additional drugs. Avoids the need for cephalosporin + metronidazole two-drug regimen.
   • (a) Advantage: single-agent convenience
   • (b) Status: acceptable alternative, NOT first-line over metronidazole-based combinations
   • © Compared against: cefuroxime + metronidazole, ampicillin-sulbactam, amoxicillin-clavulanate, piperacillin-tazobactam (for severe/healthcare-associated)
   • ℹ️ Indian alternative:Cefoxitin 2 g IV q6h (single-agent cephamycin) OR Cefuroxime 1.5 g IV q8h + Metronidazole 500 mg IV q8h (NLEM-listed combination) OR Ampicillin-sulbactam 3 g IV q6h OR Amoxicillin-clavulanate 1.2 g IV q8h
2. When NOT to use: ⛔ Healthcare-associated IAI (likely MDR gram-negatives — need piperacillin-tazobactam or carbapenem). ⛔ ESBL-producing organisms documented. ⛔ Perforated upper GI (minimal anaerobic burden — simpler regimen adequate). ⛔ Tertiary peritonitis (ICU-level care with broader-spectrum regimens).
3. NLEM India: ❌ Not listed.
4. Expected response: Defervescence, improvement in abdominal signs, declining WBC/CRP within 48–72 hours. If no improvement → re-image (CT abdomen for undrained collection), consider surgical re-intervention, broaden antibiotics.
5. Culture guidance:RECOMMENDED — peritoneal fluid culture (at time of surgery/drainage) to guide de-escalation. Blood cultures if septic.
6. Indian guideline source: API Textbook — Peritonitis chapter; ICMR AMR Guidelines 2019; SIS/IDSA Intra-abdominal Infection Guidelines 2010 (adapted for Indian practice).
7. Key safety warning: ⚠️ Source control (surgery/drainage) is the cornerstone of IAI management. Antibiotics without source control will fail. ⚠️ NMTT risk: post-operative cefotetan use in patients who are NPO, malnourished, or have liver disease → high coagulopathy risk. Monitor PT/INR. Vitamin K₁ 10 mg prophylaxis recommended.

---

1. When to prefer: ONLY for culture-confirmed susceptible organisms causing complicated UTI (pyelonephritis, urosepsis) when an IV agent with combined aerobic + anaerobic coverage is desired (e.g., suspected polymicrobial UTI in catheterised patients with concomitant intra-abdominal pathology).
   • (a) Advantage: combined coverage; q12h convenience
   • (b) Status: NOT first-line for any UTI indication
   • © Compared against: IV ceftriaxone (broader gram-negative, NLEM-listed), IV amoxicillin-clavulanate, oral nitrofurantoin/fosfomycin (for uncomplicated)
   • ℹ️ Indian alternative:IV ceftriaxone 1–2 g q24h (NLEM, once-daily, widely available) OR IV amoxicillin-clavulanate 1.2 g q8h (if enterococcal coverage also desired)
2. ⚠️ India-specific ESBL limitation: Do NOT use cefotetan (or any cephamycin) empirically for UTI in India — ESBL prevalence among uropathogens is 20–70%. Urine C&S MANDATORY before starting.
3. NLEM India: ❌ Not listed. For UTI: NLEM-listed options include ceftriaxone (injection), nitrofurantoin, amoxicillin.
4. Culture guidance:MANDATORY — urine C&S before starting treatment for any UTI indication.

---

1. When to prefer: Mixed aerobic-anaerobic SSTIs (e.g., diabetic foot infection [non-severe, non-ischaemic], post-surgical wound infection with anaerobic component, bite wounds, perianal abscess) where a single IV agent with combined coverage is desired.
   • (a) Advantage: single-agent coverage of MSSA + anaerobes
   • (b) Status: acceptable alternative for non-severe mixed SSTIs; NOT first-line
   • © Compared against: ampicillin-sulbactam (better enterococcal coverage for diabetic foot), amoxicillin-clavulanate IV (NLEM-listed, step-down available), piperacillin-tazobactam (for severe/healthcare-associated)
   • ℹ️ Indian alternative:Ampicillin-sulbactam 3 g IV q6h OR Amoxicillin-clavulanate 1.2 g IV q8h (NLEM-listed, covers enterococci — important in diabetic foot) OR Cefazolin + Metronidazole OR Cefoxitin 2 g IV q6h
2. When NOT to use: ⛔ MRSA SSTI — cefotetan is inactive (use vancomycin, linezolid, or cotrimoxazole). ⛔ Necrotising fasciitis — surgical emergency requiring broader-spectrum IV antibiotics (carbapenem + clindamycin + vancomycin). ⛔ Pure gram-positive SSTIs (non-diabetic cellulitis) — cefazolin or cloxacillin is more appropriate and narrower-spectrum.
3. NLEM India: ❌ Not listed.

---

1. When to prefer: Aspiration pneumonia where anaerobic coverage is specifically needed alongside aerobic gram-negative coverage. ⛔ NOT for non-severe CAP (use cefuroxime, amoxicillin-clavulanate, or ceftriaxone — all NLEM-listed).
   • (a) Advantage: single-agent aerobic + anaerobic LRTI coverage (aspiration pneumonia)
   • (b) Status: acceptable alternative for aspiration pneumonia
   • © Compared against: ampicillin-sulbactam IV (standard for aspiration), ceftriaxone + metronidazole, amoxicillin-clavulanate IV
   • ℹ️ Indian alternative:Ampicillin-sulbactam 3 g IV q6h (standard for aspiration pneumonia in India) OR Amoxicillin-clavulanate 1.2 g IV q8h OR Ceftriaxone 2 g IV q24h + Metronidazole 500 mg IV q8h
2. ⚠️ India-specific: Always consider tuberculosis in non-resolving pneumonia — obtain sputum AFB smear and GeneXpert. Do NOT attribute non-resolving pneumonia to antibiotic failure without ruling out TB.
3. NLEM India: ❌ Not listed.

---

1. When to prefer: Culture-confirmed polymicrobial bone/joint infection with susceptible aerobic AND anaerobic organisms. NOT empirical first-line.
   • (a) Advantage: combined coverage for polymicrobial bone/joint infection
   • (b) Status: NOT first-line — reserve for culture-directed use
   • © Compared against: cefazolin IV (MSSA osteomyelitis — first-line), cloxacillin IV, ceftriaxone IV, linezolid (if MRSA)
   • ℹ️ Indian alternative:Cefoxitin 2 g IV q6h (culture-directed) OR pathogen-directed monotherapy based on culture (cefazolin for MSSA, ceftriaxone for susceptible gram-negatives)
2. ⛔ NOT for MRSA bone/joint infections. ⛔ NOT empirical first-line for any bone/joint infection.
3. NLEM India: ❌ Not listed.

---

IV-to-Oral Step-Down Criteria (All Indications)

• ✅ Clinically improving (reduced fever, pain, inflammatory markers)
• ✅ Afebrile for ≥24–48 hours
• ✅ Tolerating oral medications without vomiting
• ✅ Functioning GI tract (no ileus, no high-output fistula)
• ✅ No ongoing sepsis or haemodynamic instability
• ✅ No undrained collection requiring source control
• ✅ WBC trending toward normal
• ✅ Identified organism susceptible to the proposed oral agent (if culture-directed)

---

Secondary Indications — Adults Only (Off-label, if any)

---

Off-Label Indication 1: SPONTANEOUS BACTERIAL PERITONITIS (SBP) — Empirical

• ⛔ NOT recommended for SBP. Use IV ceftriaxone 2 g q24h or IV cefotaxime 2 g q8h (NLEM-listed, better evidence, superior gram-negative coverage for SBP pathogens).
• Evidence quality: Not applicable — no evidence supports cefotetan for SBP.
• Clearly marked: OFF-LABEL — NOT recommended.

---

Off-Label Indication 2: SURGICAL PROPHYLAXIS FOR EMERGENCY LAPAROTOMY (Penetrating Abdominal Trauma)

• Evidence quality: Moderate (multiple trauma surgery RCTs and meta-analyses support ≤24 hours of prophylactic antibiotics for penetrating abdominal trauma; cephamycins are one recommended class)
• Indian alternative:Cefoxitin 2 g IV q6h × ≤24 hours OR Cefuroxime 1.5 g IV + Metronidazole 500 mg IV (single pre-op dose → ≤24 hours)
• Indian source: AIIMS Trauma Surgery protocols; adapted from EAST guidelines.
• Clearly marked: OFF-LABEL but accepted standard practice internationally

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

Dosing Frequency Context

---

For q12h (Twice-Daily) Dosing — Hospital Setting

For Surgical Prophylaxis

• Pre-operative dose missed: If recognised before incision → give immediately (even if within <30 minutes of incision — some tissue levels are better than none). If recognised after incision → give ASAP — late prophylaxis provides some benefit. Document timing error.
• Intraoperative re-dosing missed: If procedure exceeded 6 hours and re-dosing not given → administer at recognition. If recognised only at end of surgery → give as post-operative dose.

---

Prolonged Non-Adherence / Drug Holiday Guidance

• No rebound effects or withdrawal syndrome.
• No immunogenicity concern (not a biologic).
• No re-titration needed — resume at full dose after any delay.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

---

A. RECONSTITUTION — Cefotetan Disodium Powder for Injection

---

B. FURTHER DILUTION FOR IV INFUSION

---

C. RATE OF ADMINISTRATION

---

D. STABILITY AFTER RECONSTITUTION

---

E. MULTI-DOSE VIAL HANDLING

---

F. Y-SITE / LINE COMPATIBILITY

---

G. SPECIAL ADMINISTRATION NOTES

---

H. STORAGE

---

I. COLD-CHAIN GUIDANCE

---

PAEDIATRIC DOSING (Specialist Only)

---

⚠️ CRITICAL AVAILABILITY AND SAFETY CAVEATS

1. Cefotetan is NOT marketed in India. Paediatric dosing below is provided for reference only — Indian paediatricians encountering cefotetan recommendations in international literature should use cefoxitin (the available Indian cephamycin) or other listed alternatives.
2. ⚠️ NMTT side chain — heightened paediatric concern: The N-methylthiotetrazole (NMTT) side chain of cefotetan poses a particularly significant risk in paediatric patients due to:
   • Neonates and young infants have lower vitamin K stores (especially if breastfed exclusively without vitamin K prophylaxis at birth)
   • Paediatric patients are more susceptible to antibiotic-associated disruption of vitamin K–producing gut flora
   • Nutritional status may be suboptimal in hospitalised Indian children
   • Concurrent NPO status (perioperative, critically ill) eliminates dietary vitamin K intake
   • Coagulopathy from cefotetan’s NMTT side chain in a paediatric surgical patient can be catastrophic — postoperative haemorrhage risk
3. 💡 For these reasons, cefoxitin (no NMTT side chain) is STRONGLY preferred over cefotetan in paediatric practice. If cefotetan is the only available cephamycin, prophylactic vitamin K₁ supplementation is MANDATORY in all paediatric patients.
4. ⚠️ Disulfiram-like reaction — paediatric relevance: While alcohol consumption is not typically a paediatric concern, many paediatric medications in India contain alcohol as an excipient (cough syrups, tonics, some oral suspensions, homoeopathic preparations). Nursing staff and caregivers must be warned to avoid ALL alcohol-containing medications during cefotetan therapy and for 72 hours after the last dose.

---

General Notes — Paediatric

---

Minimum Age Limits

---

---

Formulation Suitability for Children

---

Palatability

---

Age-Specific Pharmacokinetic Differences

---

NEONATAL DOSING

1. Cefoxitin has NO NMTT side chain → no coagulopathy risk → critically important in neonates
2. Cefoxitin has better-established neonatal dosing data
3. Cefoxitin is available in India

• Culture-confirmed intra-abdominal infection caused by organisms susceptible ONLY to cefotetan (and not to cefoxitin, ampicillin-sulbactam, or other available agents) — extremely unlikely scenario
• International transfer of a neonate already on cefotetan therapy where continuation is deemed necessary for a short period before switching to an Indian-available alternative

---

PAEDIATRIC DOSING REFERENCE TABLE

---

Primary Indications — Paediatric (Approved / Standard)

---

Paediatric Indication 1: INTRA-ABDOMINAL INFECTIONS — Community-Acquired, Culture-Directed

Patient: 6-year-old, 20 kg, with perforated appendicitis requiring appendectomy + IV antibiotics.

Dose calculation: 40 mg/kg/dose = 40 × 20 = 800 mg per dose q12h

Using 1 g vial: Reconstitute 1 g in 10 mL SWFI (concentration ~95 mg/mL). Draw 8.4 mL = ~800 mg.
Dilute in 50 mL NS, infuse over 20–30 minutes.

Mandatory concurrent order: Vitamin K₁ 2 mg IV at initiation. PT/INR at baseline, day 3, day 5.

1. When to prefer cefotetan: Only when a single-agent cephamycin providing aerobic + anaerobic coverage is specifically needed AND cefoxitin is unavailable AND no alternative regimen is feasible. This is an extremely unlikely clinical scenario in Indian paediatric practice.
   • ℹ️ Indian alternative (STRONGLY preferred):Cefoxitin 25–40 mg/kg/dose IV q6h (no NMTT risk) OR Cefuroxime 25–50 mg/kg/dose IV q8h + Metronidazole 7.5 mg/kg/dose IV q8h (both NLEM-listed) OR Ampicillin-sulbactam OR Piperacillin-tazobactam (for severe/healthcare-associated IAI)
2. When NOT to use: ⛔ Empirical neonatal necrotising enterocolitis (NEC) — use meropenem + vancomycin or piperacillin-tazobactam + vancomycin. ⛔ Healthcare-associated IAI (likely MDR organisms). ⛔ ESBL-producing organisms documented. ⛔ When cefoxitin is available (preferred — no NMTT risk).
3. NLEM India: ❌ Not listed.
4. Expected response: 48–72 hours. If no improvement → re-image (CT/USS for undrained collection), reassess surgical source control.
5. Culture guidance:RECOMMENDED — peritoneal fluid culture at surgery.
6. Indian guideline source: IAP guidelines on paediatric abdominal infections; API Textbook — Peritonitis; SIS/IDSA IAI guidelines (adapted).
7. Key safety warning: ⚠️ Vitamin K₁ supplementation is NON-NEGOTIABLE in any paediatric patient receiving cefotetan. Post-operative coagulopathy in a child with recent abdominal surgery can be life-threatening. If cefotetan is used: order vitamin K₁ concurrently on the prescription chart — do NOT rely on a separate verbal order.

---

Paediatric Indication 2: SURGICAL PROPHYLAXIS — Colorectal / GYN Paediatric Surgery

• ℹ️ Indian alternative (preferred):Cefoxitin 30–40 mg/kg IV (re-dose q2–3h intra-op) OR Cefazolin 30 mg/kg IV + Metronidazole 7.5 mg/kg IV (for colorectal/GYN procedures needing anaerobic coverage)
• For clean paediatric surgery (orthopaedic hardware): ⛔ Do NOT use cefotetan — use cefazolin alone (narrower spectrum, better MSSA coverage, no NMTT risk)
• ⚠️ Even for single-dose prophylaxis: consider vitamin K₁ 1–2 mg IV if the child has risk factors for vitamin K deficiency (malnutrition, exclusive breastfeeding without vitamin K at birth, liver disease, prolonged NPO)

---

Paediatric Indication 3: URINARY TRACT INFECTIONS — Complicated, Culture-Directed

• ℹ️ Indian alternative (preferred):IV ceftriaxone 50–75 mg/kg q24h (NLEM-listed, once-daily, no NMTT risk) OR IV cefoxitin 25–40 mg/kg q6h (if cephamycin specifically needed)
• Culture guidance: MANDATORY — urine C&S before starting. ESBL prevalence in Indian paediatric uropathogens is rising.
• NLEM India: ❌ Not listed. Ceftriaxone injection is NLEM-listed.

---

Paediatric Indication 4: SKIN AND SOFT TISSUE INFECTIONS — Moderate, Mixed Aerobic-Anaerobic

• ℹ️ Indian alternative (preferred):Amoxicillin-clavulanate 30 mg/kg/dose IV q8h (amoxicillin component; NLEM-listed) OR Ampicillin-sulbactam OR Cefoxitin 25–40 mg/kg q6h
• ⛔ NOT for MRSA SSTI — use cotrimoxazole or clindamycin
• ⛔ NOT for bite wounds as monotherapy in paediatrics — amoxicillin-clavulanate is preferred (enterococcal and Pasteurella coverage)

---

Secondary Indications — Paediatric (Off-label, if any)

• No established paediatric off-label indication. Use only under specialist supervision in exceptional circumstances when all Indian-available alternatives are contraindicated or ineffective based on culture data.
• Evidence quality: Very weak (case reports only; no paediatric off-label RCTs)
• Clearly marked: OFF-LABEL — not recommended for routine paediatric use

---

RENAL ADJUSTMENT

---

eGFR Formula Specification

---

Rationale for Renal Adjustment

---

Adult Renal Dosing Adjustment Table

---

Formulation-Specific Renal Adjustment

---

Surgical Prophylaxis in Renal Impairment

---

Paediatric Renal Adjustment

---

Augmented Renal Clearance (ARC)

• Consider shortening the dosing interval to q8h (instead of q12h) — this increases the %fT > MIC but also increases NMTT exposure per 24 hours (increased coagulopathy risk)
• If available: therapeutic drug monitoring (TDM) to confirm adequate free drug levels — rarely available for cefotetan
• ⚠️ If using q8h dosing in ARC: monitor PT/INR more frequently (every 2–3 days) and ensure vitamin K₁ prophylaxis is in place
• In practice: ARC patients with serious infections typically require broader-spectrum IV agents (piperacillin-tazobactam, carbapenems) — cefotetan is rarely the appropriate choice in this clinical context

---

HEPATIC ADJUSTMENT

---

✅ NO FORMAL HEPATIC DOSE ADJUSTMENT FOR CEFOTETAN ITSELF

---

⚠️ HOWEVER: HEPATIC DISEASE DRAMATICALLY AMPLIFIES NMTT-RELATED COAGULOPATHY

---

Additional Hepatic Considerations

• Patients with cirrhosis/chronic liver disease commonly have hypoalbuminaemia (serum albumin <3.0 g/dL)
• Cefotetan’s high protein binding (~76–91%) means that hypoalbuminaemia → increased free drug fraction → higher peak free drug levels + potentially faster clearance
• Clinical implication: may see slightly higher free drug concentrations (potentially better bactericidal effect) but also more rapid elimination and amplified NMTT toxicity per dose
• No formal dose adjustment for hypoalbuminaemia — but awareness of this PK alteration is important

---

Concurrent Hepatotoxin Note

---

Formulation-Specific Hepatic Adjustment

---

Summary Table: Hepatic Safety of Cefotetan vs Indian-Available Cephamycin (Cefoxitin) in Liver Disease

---

PREGNANCY

---

Overall Safety Statement

---

Trimester-Specific Risk Assessment

---

Teratogenicity Window

---

Preferred Alternatives in Indian Obstetric Practice

---

Monitoring During Pregnancy

• Mother: Standard adverse effect monitoring. ⚠️ If cefotetan used in third trimester or peripartum: check maternal PT/INR. Administer vitamin K₁ prophylaxis.
• Neonate: ⚠️ If the mother received cefotetan within 7 days before delivery: ensure the neonate receives vitamin K₁ 1 mg IM at birth (standard neonatal vitamin K prophylaxis — should be given to ALL neonates in India regardless of antibiotic exposure, but is especially critical here). Monitor neonatal PT/INR if any bleeding signs (cephalhaematoma expansion, umbilical oozing, unexpected bruising).

---

Pre-Conception Counselling

---

Pregnancy Prevention Programme / Registry

---

Fertility Effects

---

LACTATION

---

Overall Compatibility

---

⚠️ NMTT-Specific Lactation Consideration

• Preterm or very low birth weight infants
• Infants who did NOT receive vitamin K₁ at birth
• Infants with liver disease or cholestasis (impaired vitamin K cycling)

---

What to Monitor in the Breastfed Infant

• Loose stools / mild diarrhoea (most common — transient, due to alteration of gut flora)
• Oral candidiasis (thrush) — uncommon
• Unexplained bruising or bleeding (extremely rare — NMTT-related; relevant only if infant’s vitamin K status is compromised)
• Allergic skin rash (very rare)

---

Timing Advice

---

Effect on Milk Production

---

Temporary Incompatibility

---

ELDERLY

---

Definition

---

Dosing in Elderly

---

PK Considerations in Elderly

---

Extra Risks Specific to Elderly

---

Anticholinergic Burden

---

Beers Criteria / STOPP-START Relevance

---

Deprescribing Guidance

---

MAJOR DRUG INTERACTIONS

---

---

Major Food-Drug Interactions

---

Herb-Drug / Traditional Medicine Interactions (Major)

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

---

Very Common (≥10%)

---

Common (1–10%)

---

Dose-Response Threshold

• Diarrhoea and GI effects: Modestly dose-dependent — more common at 2 g q12h than 1 g q12h and with courses >7 days.
• Phlebitis: More common with concentrated solutions (>40 mg/mL) and rapid infusion.
• NMTT-related effects (hypoprothrombinemia): Clearly dose- and duration-dependent — onset typically after 3–5 days, more severe with higher total daily doses and prolonged courses. See Serious Adverse Effects.

---

SERIOUS ADVERSE EFFECTS

---

---

⚠️ SIGNATURE ADR: NMTT-Induced Hypoprothrombinemia / Coagulopathy

• ⚠️ Do NOT re-challenge with cefotetan after clinically significant NMTT-induced coagulopathy. Switch to cefoxitin (same spectrum, no NMTT) or other appropriate alternative.
• The NMTT-related coagulopathy is a predictable, dose/duration-dependent pharmacological effect — NOT an idiosyncratic/allergic reaction. Re-exposure will reproduce the effect. Unlike true drug allergy, this is a toxicity that can be prevented (vitamin K₁ prophylaxis) or managed — but re-challenge without compelling reason is not justified when alternatives exist.

• ⚠️ The NMTT-related coagulopathy will also occur with OTHER NMTT-containing beta-lactams: cefamandole, cefoperazone (available in India), and moxalactam/latamoxef. Avoid ALL NMTT-containing drugs after cefotetan-induced coagulopathy.
• ✅ Safe alternatives: Cefoxitin, cefazolin, cefuroxime, ceftriaxone, cefepime, ampicillin-sulbactam, amoxicillin-clavulanate, piperacillin-tazobactam, carbapenems — NONE of these contain the NMTT side chain.

---

Other Serious Adverse Effects

---

Antidote / Reversal Information

---

CDSCO Safety Alerts / Black Box Warnings

• Disulfiram-like reaction with alcohol (NMTT)
• Hypoprothrombinemia (NMTT) — with recommendation for vitamin K prophylaxis in at-risk patients
• CDI risk
• Haemolytic anaemia (Coombs-positive)

---

LABORATORY TEST INTERFERENCE

---

---

MONITORING REQUIREMENTS

---

⚠️ NMTT-SPECIFIC MONITORING — THE MOST CRITICAL MONITORING CONSIDERATION FOR CEFOTETAN

---

Baseline (Before Starting)

---

After Initiation / Dose Change

---

Long-Term / Maintenance Monitoring

---

Therapeutic Drug Monitoring (TDM)

---

When to Stop Monitoring

• For single-dose surgical prophylaxis: PT/INR recheck is NOT routinely needed (single dose rarely causes significant coagulopathy in patients without risk factors). If risk factors present (anticoagulated, liver disease, malnutrition): check PT/INR on post-operative day 1.
• For short courses (≤5 days): PT/INR at day 3 is the minimum. If normal and no risk factors: no further coagulation monitoring needed.
• For courses >5 days: Continue PT/INR monitoring every 3–5 days until course completion + 72 hours after last dose (NMTT effect persists).

---

ℹ️ Common Investigation Misconception Flag

---

Resource-Limited Setting Surrogates — Summary Table

---

PATIENT COUNSELLING

---

What This Medicine Is For

---

How It Is Given

• ”This medicine is given by the nurse through your drip (IV line) over 20–60 minutes, or as an injection into the muscle. You do NOT take this medicine by mouth.“
• ”You will usually receive this medicine twice a day (every 12 hours — for example, 8 AM and 8 PM).“
• ”If you are receiving this medicine before surgery (to prevent infection): you will get one dose before the operation. You do NOT usually need it after the surgery.“

---

⚠️ The Most Important Warning — NO ALCOHOL

• ”If you drink alcohol (even a small amount), this medicine will react with the alcohol in your body and cause a very unpleasant and potentially dangerous reaction: severe nausea, vomiting, flushing (face turning red and hot), fast heartbeat, headache, dizziness, and in severe cases, your blood pressure can drop dangerously low.“
• "This includes ALL types of alcohol:
  • Beer, wine, spirits (whisky, rum, vodka, brandy, toddy, arrack)
  • ⚠️ Ayurvedic asava/arishta medicines (like Ashwagandharishta, Draksharishta, Dashmularishta) — these contain alcohol even though they are ‘herbal’
  • ⚠️ Homoeopathic tinctures (mother tinctures) — these are alcohol-based
  • ⚠️ Cough syrups and tonics — many contain alcohol. Ask your pharmacist or doctor before taking any cough syrup, tonic, or supplement
  • Alcohol-based mouthwash (if you swallow any)
  • Alcohol-based hand sanitisers applied to large areas of broken skin (unlikely to cause reaction from intact skin)"
• ”This rule applies even AFTER you leave the hospital — avoid all alcohol and alcohol-containing products for 3 full days after your last dose of this medicine.“

---

Warning About Bleeding Risk

• ”Unusual bruising (blue/black marks on your skin that you did not expect)“
• ”Oozing or bleeding from your drip site, surgical wound, or any cut“
• ”Bleeding from your gums when brushing teeth“
• ”Blood in your urine (red or dark brown urine)“
• ”Black or bloody stools“
• ”Nosebleeds that do not stop easily“
• ”Any unusual bleeding anywhere“

---

Common Side Effects to Expect

• ”You may get loose stools or mild diarrhoea — this is common. Tell your nurse if the diarrhoea is severe, bloody, watery, or comes with stomach cramps and fever.“
• ”The area around your drip may become slightly sore or red — tell the nurse so they can change the drip site.“
• ”If you get the medicine as a muscle injection, it may be painful at the injection site — this is normal and usually gets better within a day.“

---

Warning Signs — Tell Your Nurse/Doctor Immediately

• ⚠️ ”Difficulty breathing, swelling of face/lips/tongue/throat — this is an emergency“
• ⚠️ ”Severe skin rash with blisters, peeling, or sores in your mouth/eyes“
• ⚠️ ”Severe diarrhoea (bloody, watery, many times a day) with fever — can happen even weeks after you stop this medicine“
• ⚠️ ”Any unexplained bleeding or bruising (see list above)“
• ⚠️ ”Yellow colour of eyes or skin“

---

Things to Avoid

• ⛔ ALL alcohol and alcohol-containing products — during treatment AND for 72 hours after last dose (see detailed list above)
• ”Tell your doctor about ALL medicines you are taking — especially blood-thinning medicines (warfarin / Acitrom)“
• ”Tell your doctor about ALL Ayurvedic, homoeopathic, or herbal medicines you are taking“

---

Duration

• ”This medicine is for a specific course to treat your infection. The length of the course depends on the type of infection.“
• ”Your doctor will decide when to stop this medicine and may switch you to a different antibiotic taken by mouth.“

---

Follow-Up

• ”Your doctor will order blood tests (to check your blood clotting and kidney function) during your treatment.“
• ”After leaving the hospital, come back if: diarrhoea develops (even weeks later), unusual bleeding or bruising occurs, or your symptoms return.“

---

Common Patient Questions

---

Caregiver / Family Counselling

• ✔ ⛔ No alcohol — ensure the family does NOT bring alcohol-containing beverages, tonics, Ayurvedic asava/arishta, homoeopathic tinctures, or alcohol-containing cough syrups to the patient during hospitalisation or for 3 days after discharge
• ✔ Bleeding watch — alert nursing staff immediately if they notice new bruising, bleeding from drip/wound site, blood in urine/stool, or nosebleed
• ✔ Post-discharge diarrhoea — if severe/bloody diarrhoea develops even weeks after discharge, bring the patient back to hospital (CDI risk)
• ✔ Complete the course — if the patient is switched to oral antibiotics at discharge, ensure the full prescribed course is completed
• ✔ Vitamin K₁ — if the patient is discharged on oral antibiotics after receiving cefotetan IV, remind the family that any remaining bleeding risk from cefotetan will resolve within 72 hours. No ongoing vitamin K supplementation is usually needed after discharge unless specifically prescribed.

---

India-Specific Adherence Support

---

BRANDS AVAILABLE IN INDIA

---

⛔ NO BRANDS AVAILABLE IN INDIA

• ❌ No Jan Aushadhi / PMBJP brand
• ❌ No private Indian brands
• ❌ No government supply
• ❌ No NLEM listing

---

Historical / International Brand (For Reference Only)

---

Indian Alternative — Cefoxitin Brands

---

PRICE RANGE (INR)

---

Cefotetan

---

Comparative Cost Context — Indian-Available Alternatives

---

CLINICAL PEARLS

---

---

---

---

---

---

• Single-agent substitute: Cefoxitin 2 g IV within 60 min of incision (re-dose q2–3h intra-op for long cases) — provides combined aerobic + anaerobic coverage in one drug, no NMTT risk, no special monitoring.
• Two-agent substitute: Cefazolin 2 g IV + Metronidazole 500 mg IV within 60 min of incision — cefazolin provides better MSSA coverage than cefoxitin (advantageous for wound infection prevention), metronidazole provides reliable anaerobic coverage (no cephamycin resistance issue), both are NLEM-listed, both are cheap. Cefazolin’s longer half-life (re-dose q4h) is more convenient than cefoxitin’s (re-dose q2–3h).
• Either option is pharmacologically appropriate, safe, and available in India.

---

VERSION

---

REFERENCES

1. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (editors). Chapter: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. Pharmacology of cephamycins (cefotetan, cefoxitin), mechanism of action, PK/PD of beta-lactams, NMTT side chain pharmacology (disulfiram-like reaction mechanism, hypoprothrombinemia mechanism), spectrum of activity, cephalosporin/cephamycin classification, comparative pharmacokinetics (half-life, protein binding, renal elimination), allergy cross-reactivity between beta-lactam subclasses.
2. Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Jameson JL, Fauci AS, Kasper DL, et al. (editors). Chapters: Treatment of Bacterial Infections, Pelvic Inflammatory Disease, Intra-Abdominal Infections, Surgical Site Infection Prevention, Antimicrobial Resistance.
3. National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Referenced to confirm cefotetan is NOT NLEM-listed. Referenced for NLEM-listed alternatives: cefazolin injection (1 g), cefuroxime injection (750 mg, 1.5 g), metronidazole injection (500 mg/100 mL), amoxicillin-clavulanate (tablet 500/125 mg; injection 1000/200 mg), ampicillin injection, ceftriaxone injection, vitamin K₁ injection.
4. National Formulary of India, 6th Edition (2021) — Indian Pharmacopoeia Commission. Cephalosporin class monograph. General dosing, adverse effects, pharmacokinetics. Referenced for cefoxitin monograph data (the Indian-available cephamycin).
5. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2019 — Indian Council of Medical Research. Guidance on empirical antibiotic selection, antimicrobial stewardship, ESBL prevalence data in India (used for resistance context throughout this monograph). Referenced for recommendation against cephamycin use for ESBL infections.
6. API Textbook of Medicine, 11th Edition — Association of Physicians of India. Chapters on: Intra-Abdominal Infections/Peritonitis, Pelvic Inflammatory Disease, Surgical Site Infections, Antimicrobial Stewardship, Anaerobic Infections.
7. CDC STI Treatment Guidelines, 2021 — Centers for Disease Control and Prevention (US). Referenced for: PID treatment Regimen A (cefotetan-based) and Regimen B (cefoxitin-based), with Indian adaptation notes (using cefoxitin as the available cephamycin in India). CDC guidelines are widely used by Indian O&G specialists for PID management.
8. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Am J Health-Syst Pharm 2013; 70:195–283 (ASHP/IDSA/SIS Surgical Prophylaxis Guidelines). Referenced for: surgical prophylaxis recommendations for colorectal, gynaecological, and clean-contaminated procedures. Cefotetan is specifically listed as an option for these procedures in these guidelines.
9. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133–164 (SIS/IDSA IAI Guidelines). Referenced for: IAI treatment recommendations and role of cephamycins in community-acquired IAI.
10. FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines — Referenced for: C-section prophylaxis recommendations (cefazolin as first-line), PID management in Indian obstetric practice.
11. IAP (Indian Academy of Pediatrics) Guidelines — Referenced for: neonatal sepsis regimen (ampicillin + gentamicin — standard per NNF/IAP/WHO), paediatric intra-abdominal infections, paediatric antibiotic selection.
12. NNF (National Neonatology Forum of India) Clinical Practice Guidelines — Neonatal Sepsis: Diagnosis and Management. Referenced for: standard neonatal sepsis regimen and recommendation against cefotetan use in neonates.
13. AIIMS Treatment Guidelines / Protocols — All India Institute of Medical Sciences, New Delhi. Referenced for: surgical prophylaxis protocols, antimicrobial stewardship framework, empirical antibiotic selection for IAI and PID.
14. NCDC (National Centre for Disease Control) Infection Control Guidelines — Referenced for: surgical prophylaxis recommendations adapted for Indian hospital settings.
15. NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) — Referenced to confirm cefotetan is NOT under NPPA price control (not marketed in India). Referenced for NPPA-controlled pricing of alternatives (cefuroxime, metronidazole, amoxicillin-clavulanate, cefazolin).
16. PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue. Referenced to confirm cefotetan is NOT available through Jan Aushadhi stores.
17. CDSCO Approved Drug List and Banned Drug List — Referenced to confirm cefotetan is NOT currently CDSCO-approved/marketed in India and has NOT been banned (never marketed).
18. PvPI (Pharmacovigilance Programme of India) — ADR reporting guidelines and mechanism. Central Drugs Standard Control Organisation. Available at cdsco.gov.in. Helpline: 1800-180-3024.
19. NACO (National AIDS Control Organisation) / ICMR National Treatment Guidelines for Gonorrhoea — Referenced for recommendation that cefotetan/cefoxitin should NOT be used for gonorrhoea (gonococcal resistance) — ceftriaxone is current first-line.
20. Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission. Referenced for: cefoxitin sodium monograph (the Indian-available cephamycin).

---